GBC Blog

U.S. Department of Veterans Affairs Awards Supply Contract for Epi proColon Berlin (Germany) and Germantown, MD (U.S.A.), March 3, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced that the U.S. Department of Veterans Affairs has awarded Epigenomics’ distribution partner Polymedco, Inc. with a five-year supply contract for Epi proColon, commencing March…

Epigenomics Joins Forces with hundreds of Organizations to Increase Colorectal Cancer Screening Rates in the United States “80% by 2018” is a shared goal to have 80% of adults aged 50 and older screened for colorectal cancer by 2018 – Colorectal cancer screening has been proven to save lives Berlin (Germany) and Germantown, MD (U.S.A.),…

Asterand Bioscience and MolecularMD announce a partnership to accelerate targeted therapeutic biomarker validation, optimization, development and commercialization  — PORTLAND, OR and CAMBRIDGE, MA and DETROIT, MI–( – February 15, 2017) – Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced today a partnership…

Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers – Completion of EMEA Direct Sales team build-out drives 46% growth in system installations over the course of 2016 – Reported unaudited FY 2016 revenue and strong year-end cash position Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 31, 2017 – Curetis N.V. (Euronext: CURE, the…

Journal of “Cancer Treatment and Research Communications” Publishes Results of Study with Blood Test Epi proColon® ADMIT Study Results Demonstrate Higher Uptake of a Colorectal Cancer Screening Blood Test Compared to a Fecal Test 11.01.2017 Berlin (Germany) and Germantown, MD (U.S.A.), January 11, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that…

ARUP Laboratories to Offer Epi proColon®, Epigenomics’ Blood-Based Colorectal Cancer Screening Test (Press Release) Berlin (Germany) and Germantown, MD (U.S.A.), November 8, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that ARUP Laboratories (Salt Lake City, Utah) is the next major U.S. laboratory to offer Epi proColon®, the first and only FDA-approved…

USPSTF Guidelines May Have Used Old Data on Epigenomics Colorectal Cancer Screening Test Oct 26, 2016 NEW YORK (GenomeWeb) – The US Preventive Services Task Force (USPSTF) failed to take into account the most recent data available on Epigenomics’ Epi proColon colorectal cancer screening test when warning about its relatively low efficacy in recently updated…

New Legislation Would Require CMS Coverage for Blood-Based Colorectal Cancer Screens Sep 29, 2016 | GenomeWeb [Original Article] NEW YORK – A bipartisan group of Congressional representatives today unveiled a bill that would require Medicare coverage for qualifying US Food and Drug Administration-approved blood-based colorectal cancer screening tests in order to boost screening in traditionally…